FIT Biotech Oy: Liquidity providing agreement between FIT Biotech Oy and FIM Sijoituspalvelut transferred to S-Pankki – FIT Biotech

Reports and Releases

FIT Biotech Oy: Liquidity providing agreement between FIT Biotech Oy and FIM Sijoituspalvelut transferred to S-Pankki

FIT Biotech Oy

Company release Mach 1st, 2016 at 9.00 am EET   


Liquidity providing agreement between FIT Biotech Oy and FIM Sijoituspalvelut transferred to S-Pankki

FIM Sijoituspalvelut Oy has informed that it's brokerage, clearing and custody services will be transferred to S-Pankki as part of the group's internal business transaction. Therefore Liquidity providing agreement between FIT Biotech Oy and FIM Sijoituspalvelut Oy will be transferred to S-Pankki Oy as of March 1, 2016.

FIT BIOTECH OY

Board of Directors

Further information:
Rabbe Slätis
CEO
FIT Biotech Oy
Telephone: +358 40 840 6749
Email: rabbe.slatis@fitbiotech.com

Certified Advisor: Translink Corporate Finance Oy, telephone +358 20 743 2790


FIT Biotech Oy in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq Helsinki Oy.


DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com

Back to list